BioSpace News Archive

Edison Oncology Holding Corp. (“Edison Oncology”), a privately held biopharmaceutical company, is pleased to announce the presentation of two scientific posters at the annual meeting of the American Association of Cancer Research held in Orlando, Florida from April 14-19.

The Insight Partners published latest research report on “Structural Heart Market Size Report, Share, Growth, Trends, Forecast to 2028 - COVID-19 Impact and Global Analysis By Product, Procedure, and End User” the global market size was valued at USD 14,245.55 million in 2022

IQVIA™ announces the company has been recognized as a Leader in Customer Experience Platforms by Everest Group for its Orchestrated Customer Engagement platform.

Marvel Biosciences Corp. (TSXV: MRVL) and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the “Company” or “Marvel”), is pleased to announce that it has completed the dosing portion of the 4-week good laboratory practice (GLP) FDA investigational new drug (IND) enabling dose-ranging dog and rat studies for its lead drug candidate MB-204.

Rakovina Therapeutics Inc. (the “Company”) (TSXV:RKV) today announced the presentation of new data describing the progress of the Company’s kt-3000 drug development program at the American Association of Cancer Research (AACR) annual meeting in Orlando, Florida.

Hyperfine, Inc., the groundbreaking medical device company that created the Swoop® system, the world’s first FDA-cleared portable MRI system™, announced that it will report financial results for the first quarter 2023 on Thursday, May 11, 2023.

QIAGEN announced that Steve Rusckowski, an internationally recognized healthcare industry executive and former Chairman, President and CEO of Quest Diagnostics, has joined the Supervisory Board as a new member and will stand for election at the next Annual General Meeting scheduled for June 22, 2023.

Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced that it will report its financial results for the first quarter of 2023 on Thursday, May 4, 2023, following the close of market.

Indaptus Therapeutics, Inc., a biotechnology company focused on discovering and developing transformative therapeutics for patients, announces that CEO Jeffrey A. Meckler will present a corporate overview at the Planet MicroCap Showcase: VEGAS 2023.

Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system cancers, today announced financial results for the first quarter ended March 31, 2023, and provided an overview of recent business highlights.